Posted by Michael Wonder on 20 Sep 2024
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
19 September 2024 - MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA.
Bavarian Nordic announced today that the European Commission has adopted the CHMP recommendation for the approval of a type II variation for Imvanex smallpox and mpox vaccine, extending the current marketing authorisation to include adolescents 12 to 17 years of age.
